Hydantoins Derived from Ketopinic and 4-camphorcarboxylic Acids by Knizhnikov, Volodymyr et al.
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2013, VOLUME 1, ISSUE 1)  
23 
Hydantoins derived from ketopinic and 4-camphorcarboxylic acids 
Volodymyr O. Knizhnikov
a
, Zoia V. Voitenko
a
, Marian V. Gorichko
a
 
 
a Department of Chemistry, Kiev University, Volodymyrska St. 64, Kiev 01033, Ukraine 
 
gorichko@chem.univ.kiev.ua 
  
Diastereospecific formation of hydantoins from ketopinic and 4-camphorcarboxylic acids under 
Bucherer-Bergs reaction conditions has been investigated. The easiness of this transformation 
provides a straightforward synthetic pathway to enantiopure conformationally rigid amino acids 
derivatives, as well as functionalized hydantoins, starting from inexpensive and easily available 
natural camphor. 
 
Introduction 
Specific arrangement of functional 
groups combined with rigidity of the 
conformationally restricted molecules enables, 
in favourable cases, key-in-the-lock fit 
combined with efficient intermolecular 
interaction. It is noteworthy that there are 
examples of improvements in performance 
achieved using this strategy, where better 
selectivity of the system coincided with higher 
activity and superior stability. 
Hydantoins, also known as glycolylureas, are 
important moieties found in numerous natural 
products [1–3]. Hydantoin-based scaffolds often 
show interesting and significant 
pharmacological activities [1,4–9]. One the 
best-known example of such a derivative is 5,5-
diphenylhydantoin (phenytoin), a commonly 
used antiepileptic (also anti-convulsant and 
cardiac antiarrhythmic) [4,5,10–12]. A wide 
range of hydantoin derivatives, such as 3-
substituted-5-phenyl-5-pyridyl hydantoins, has 
been identified as effective and important 
cardiac antiarrhythmic agents [13]. This 
particular range of compounds have also shown 
good antidepressant, antimuscarinic and 
antiviral activities [5,6,14,15]. Recently, 5-
substituted hydantoins have been reported to 
inhibit the binding of human immunodeficiency 
viruses to lymphocytes [16,17]. Substituted 
hydantoins are an important class of precursors 
to α-amino acids and pyruvic acids, which can 
be easily synthesized via alkaline degradation of 
the former [18–20]. 
The Bucherer-Bergs reaction is an important 
synthetic pathway to hydantoins using a wide 
range of aldehydes and ketones, including those 
with low reactivity of the carbonyl group 
[21,22]. 
The Nature itself perfected rigid 
biologically vital molecules over millions of 
years. However, such timescale is simply a 
luxury science and industry could not afford. 
Development of versatile synthetic pathways 
towards conformationally rigid molecules is 
therefore of paramount importance. We hereby 
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report our approach towards selective synthesis 
of conformationally rigid bio-relevant 
molecules starting from readily available natural 
feedstocks. 
 
Results and discussion 
Camphor and its derivatives have attracted the 
interest of many organic chemists as an easily 
accessible and versatile starting material in the 
synthesis of chiral compounds. To the best of 
our knowledge, only the parent hydantoin of 
camphor has been previously reported, despite 
the fact that there is a huge variety of camphor 
derivatives containing carbonyl groups [23]. 
Herein, we have chosen ketopinic and 4-
camphorcarboxylic acids, which contain 
carbonyl groups with slightly different 
reactivities, as the best substrates from the 
family of camphor derivatives for a study of 
regio- and diastereoselectivity of the formation 
of hydantoins under Bucherer-Bergs reaction 
conditions. 
Camphor itself forms a mixture of 
diastereomeric hydantoins (7:3) under 
Bucherer-Bergs reaction conditions (KCN, 
(NH4)2CO3, 120 °С, 10 atm, 5 h). The major 
product contains carboxamide carbonyl group in 
endo position, since the endo attack of cyanide 
anion on carbonyl group of camphor is 
preferable due to the steric hindrance of methyl 
group in bridge position [23]. 
Ketopinic (1) and 4-camphorcarboxylic acid (2) 
form hydantoins in much milder reaction 
conditions (at a lower pressure and temperature) 
and faster than camphor does. Unlike camphor, 
which gives a mixture of diastereomeric 
hydantoins, the keto acids 1 and 2 give only one 
isomer – a product of cyanide ion attack from 
endo side of the norbornane skeleton (Scheme 
1). 
The NOE interaction between protons of amide 
group (NHCO) and methyl group (CH3) at C-8 
atom of camphor skeleton confirms the 
suggested structures of hydantoins (3 and 4). 
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Scheme 1. Hydantoins formation from β- and γ-keto 
carboxylic acids. 
The presence of carboxyl groups at the 
bridgehead positions in β- and γ-keto acids 1 
and 2 ensures easy and diastereospecific 
formation of corresponding hydantoins due to 
synergistic pre-organisation of reacting species. 
Conclusions 
In conclusion, we have studied the 
diastereospecific formation of hydantoins from 
ketopinic and 4-camphorcarboxylic acids under 
Bucherer-Bergs reaction conditions. The 
easiness of this transformation opens a 
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straightforward synthetic pathway to 
enantiopure derivatives of bridgehead 
norbornane carboxylic acids. The described 
route provides a model procedure for the 
preparation of other interesting norbornane-
based functionalized compounds. 
 
Experimental part 
 All the starting materials were purchased 
from Acros, Merck, Aldrich and Fluka 
chemicals. All solvents were distilled before use 
[26]. All experiments, unless otherwise stated, 
were carried under a nitrogen atmosphere. The 
1
H and 
13
C NMR spectra were recorded on a 
‘Mercury 400’ Varian and Bruker AM 400 (400 
MHz) spectrometers. Tetramethylsilane was 
used as the internal standard. IR spectra were 
obtained on a Perkin Elmer BX II spectrometer. 
νmax (cm
-1
) values in IR spectra are given for the 
main absorption bands. Mass spectra ware 
recorded on an Agilent 1100 LSMS SL 
instrument with chemical ionization.  
 
General method of hydantoins preparation.  
A solution of 5 mmol of keto acid 1 or 2 in 10 
mL of ethanol in steel autoclave (ca. 100 mL of 
total volume), containing a magnetic stirrer, was 
quickly charged with a solution of 4.80 g (50 
mmol) of ammonium carbonate in 20 mL of 
water and 1.30 g (20 mmol) of potassium 
cyanide in 10 mL of distilled water. The 
autoclave was sealed and left to stir at 10 bar 
pressure of CO2 and 100 ºC for 4 h. The 
reaction mixture was then cooled to room 
temperature, transferred into a round bottom 
flask, and evaporated. The residue was 
dissolved in 10 mL of water and acidified to pH 
= 4. The resulting solid product was filtered and 
washed with small amount of cold water. 
 
Hydantoin of 7,7-dimethyl-2-
oxobicyclo[2.2.1]heptane-1-carboxylic acid (3) 
Yield: 65%. Mp: 245 ºC (dec.). 
1
Н NMR (400 
МHz, [D6]DMSO): δ = 1.08 (s, 3Н), 1.17 (s, 
3Н), 1.25–1.35 (m, 1Н), 1.60–1.80 (m, 4Н), 
1.95–2.07 (m, 1Н), 2.55–2.60 (m, 1Н), 7.52 (br 
s, 1Н), 10.65 (br s, 1Н). 12.35 (br s, 1Н).
 13
C 
{
1
H} NMR (75 MHz, CDCl3): δ = 21.0, 21.2, 
25.6, 26.0, 43.0, 45.4, 50.2, 62.5, 68.5, 157.2, 
173.0, 177.8. MS (CI): m/z 253.3 (M+H). 
C12H16N2O4 (252.3): calcd C 57.13, H 6.39, N 
11.10; found C 57.10, H 6.45, N 11.06. 
 
Hydantoin of 4,7,7-trimethyl-3-
oxobicyclo[2.2.1]heptane-1-carboxylic acid (4) 
Yield: 69%. Mp: 265 ºC (dec.). 
1
Н NMR (400 
МHz, [D6]DMSO): δ = 0.77 (s, 3Н), 0.87 (s, 
3Н), 0.91 (s, 3Н), 1.30–1.40 (m, 1Н), 1.45–1.60 
(m, 1Н), 1.90–2.10 (m, 3Н), 2.28 (d, J = 15,6 
Hz, 1Н), 7.51 (br s, 1Н), 10.68 (br s, 1Н), 12.25 
(br s, 1Н).
 13
C {
1
H} NMR (75 MHz, CDCl3): δ 
= 11.3, 18.9, 19.6, 27.5, 29.7, 44.3, 53.3, 55.5, 
56.2, 69.3, 156.9, 174.4, 177.6. MS (CI): m/z 
267.3 (M+H). C13H18N2O4 (266.3): calcd C 
58.64, H 6.81, N 10.52; found C 58.60, H 6.87, 
N 10.49. 
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